home / stock / mscl:cc / mscl:cc quote
Last: | $0.93 |
---|---|
Change Percent: | -2.11% |
Open: | $0.93 |
Close: | $0.93 |
High: | $0.96 |
Low: | $0.89 |
Volume: | 50,284 |
Last Trade Date Time: | 05/06/2022 04:56:05 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.93 | $0.93 | $0.93 | $0.96 | $0.89 | 50,284 | 05-06-2022 |
$0.95 | $0.96 | $0.95 | $1 | $0.89 | 75,002 | 05-05-2022 |
$1 | $1.08 | $1 | $1.08 | $1 | 40,269 | 05-04-2022 |
$1.1 | $1.08 | $1.1 | $1.12 | $1 | 62,204 | 05-03-2022 |
$1.12 | $0.9 | $1.12 | $1.18 | $0.9 | 136,226 | 05-02-2022 |
$0.98 | $1.07 | $0.98 | $1.07 | $0.98 | 53,496 | 04-29-2022 |
$1 | $1.02 | $1 | $1.1 | $1 | 31,631 | 04-28-2022 |
$1.05 | $1.14 | $1.05 | $1.15 | $1.05 | 35,677 | 04-27-2022 |
$1.14 | $1.16 | $1.14 | $1.16 | $1.07 | 51,865 | 04-26-2022 |
$1.2 | $1.15 | $1.2 | $1.2 | $1.14 | 89,773 | 04-25-2022 |
$1.14 | $1.07 | $1.14 | $1.15 | $1.07 | 86,692 | 04-22-2022 |
$1.06 | $1.07 | $1.06 | $1.08 | $1.05 | 18,135 | 04-21-2022 |
$1.08 | $1.07 | $1.08 | $1.08 | $1.05 | 12,000 | 04-20-2022 |
$1.09 | $1.05 | $1.09 | $1.09 | $1.05 | 27,624 | 04-19-2022 |
$1.1 | $1.1 | $1.1 | $1.1 | $1.07 | 24,800 | 04-18-2022 |
$1.07 | $1.08 | $1.07 | $1.09 | $1.06 | 6,458 | 04-15-2022 |
$1.07 | $1.08 | $1.07 | $1.09 | $1.06 | 6,458 | 04-14-2022 |
$1.1 | $1.05 | $1.1 | $1.1 | $1.04 | 65,997 | 04-13-2022 |
$1.08 | $1.08 | $1.08 | $1.08 | $1.05 | 11,602 | 04-12-2022 |
$1.06 | $1.09 | $1.06 | $1.1 | $1.02 | 93,580 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
Satellos Bioscience Inc. Company Name:
MSCL:CC Stock Symbol:
TSXVC Market:
Satellos Bioscience Inc. Opens the Market Canada NewsWire TORONTO , May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin , Managing Direc...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...